In particular, miR-4799-5p has been recognized as a potential biomarker for polycystic ovarian syndrome and is anticipated to target NAMPT and MAPK1, highlighting its putative involvement in the molecular pathways associated with the condition 54. This evidence concerns the gene MAPK1 and polycystic ovary syndrome.